Healthcare Services

Chronic Plaque Psoriasis Market (2026–2030): Innovation and Competitive Landscape

April 20, 2026April 20, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Does The Market Size Of The Chronic Plaque Psoriasis Market Compare Between 2026 And 2030?

The chronic plaque psoriasis market has shown strong growth recently. It is anticipated to expand from $22.26 billion in 2025 to $23.83 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.1%. This historical increase is due to improved diagnosis of autoimmune skin disorders, wider availability of topical therapies, increased awareness of psoriasis management, expansion of dermatology clinics, and improved access to specialty drugs.

The chronic plaque psoriasis market is forecast to experience substantial growth in the upcoming years. Its size is expected to increase to $30.99 billion by 2030, achieving a compound annual growth rate (CAGR) of 6.8%. This expansion during the forecast period can be attributed to the rising development of next-generation biologics, increased adoption of oral immunomodulators, the broadening of precision dermatology approaches, a growing focus on patient-centric treatment strategies, and intensified investment in autoimmune disease research. Significant trends anticipated during this period include an elevated uptake of biologic therapies, a rise in the use of targeted small molecule drugs, a greater emphasis on personalized dermatology care, an expansion of available oral treatment options, and an enhanced focus on long-term disease management.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/chronic-plaque-psoriasis-global-market-report

What Significant Factors Are Influencing The Chronic Plaque Psoriasis Market Expansion?

The rising incidence of immune system dysfunction is anticipated to drive the expansion of the chronic plaque psoriasis market in the future. This condition denotes a state where the immune system does not function optimally, consequently heightening vulnerability to infections, autoimmune disorders, and various cancers. The surge in immune system dysfunction cases is linked to factors including genetic predispositions, environmental stimuli, nutritional deficiencies, persistent stress, and the increasing occurrence of autoimmune diseases and infections such as HIV. Management of immune system dysfunction often necessitates chronic plaque psoriasis treatment, as the immune system’s erroneous activation leads to an excessive proliferation of skin cells, resulting in inflammation and the development of plaques. For example, in February 2024, data from Arthritis Australia, an Australia-based non-profit organization, indicated that an estimated 212,136 males and 362,137 females are projected to have rheumatoid arthritis (RA) in 2025, with these figures anticipated to climb by 2040 to approximately 280,040 males and 479,828 females. Thus, the expanding prevalence of immune system dysfunction is a key force propelling the growth of the chronic plaque psoriasis market.

Which Segment Types Are Examined In The Chronic Plaque Psoriasis Market Segment Study?

The chronic plaque psoriasis market covered in this report is segmented –

1) By Drug Class: Biologics, Small Molecule Drugs

2) By Route Of Administration: Injectable, Oral, Topical

3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy

Subsegments:

1) By Biologics: Tumor Necrosis Factor (TNF) Inhibitors, Interleukin Inhibitors (IL-12, IL-23, IL-17, IL-22), T-Cell Inhibitors

2) By Small Molecule Drugs: Phosphodiesterase 4 (PDE4) Inhibitors, Janus Kinase (JAK) Inhibitors, Retinoids

What Trends Are Affecting The Direction Of The Chronic Plaque Psoriasis Market?

Leading companies in the chronic plaque psoriasis market are concentrating on developing advanced treatments, such as IL-17A and IL-17F inhibitors, to improve therapy for chronic plaque psoriasis. These IL-17A and IL-17F inhibitors are targeted biologic therapies that work by blocking interleukin-17A and interleukin-17F, which are pro-inflammatory cytokines involved in the immune response, thereby reducing inflammation in autoimmune conditions like chronic plaque psoriasis. For example, in October 2023, UCB S.A., a biopharmaceutical company based in Belgium, announced that the U.S. Food and Drug Administration (FDA) had approved BIMZELX (bimekizumab-bkzx) for adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Bimekizumab is the initial approved medication for psoriasis specifically designed to target and inhibit interleukin 17A (IL-17A) and interleukin 17F (IL-17F), two critical cytokines in inflammatory processes. Its approval was supported by evidence from three Phase 3 multicenter trials, namely BE READY, BE VIVID, and BE SURE, which collectively assessed its safety and efficacy in 1,480 patients with moderate to severe plaque psoriasis.

Which Players Are Part Of The Competitive Landscape Of The Chronic Plaque Psoriasis Market?

Major companies operating in the chronic plaque psoriasis market are Pfizer Inc., Johnson & Johnson, AbbVie Inc., Bristol-Myers Squibb Company, Novartis AG, Eli Lilly and Company, Amgen Inc., Dr Reddy’s Laboratories, Innovent Biologics Inc., Bio-Thera Solutions, Celgene Corporation, Arcutis Biotherapeutics, LEO Pharma A/S, Sun Pharmaceutical Industries Ltd, AstraZeneca plc, Takeda Pharmaceutical Company Limited, Biocon Ltd, Stiefel Laboratories Inc, Regeneron Pharmaceuticals, Sanofi S.A., GSK plc, Merck & Co. Inc., UCB S.A., Roche Holding AG, Evelo Biosciences Inc, Biogen Inc.

Get The Full Chronic Plaque Psoriasis Market Report:

https://www.thebusinessresearchcompany.com/report/chronic-plaque-psoriasis-global-market-report

Which Region Is The Top Contributor To The Chronic Plaque Psoriasis Market By Share?

North America was the largest region in the chronic plaque psoriasis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chronic plaque psoriasis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Chronic Plaque Psoriasis Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/chronic-plaque-psoriasis-global-market-report

Browse Through More Reports Similar to the Global Chronic Plaque Psoriasis Market 2026, By The Business Research Company

Rheumatology Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/rheumatology-therapeutics-global-market-report

Chronic Spontaneous Urticaria Market Report 2026

https://www.thebusinessresearchcompany.com/report/chronic-spontaneous-urticaria-global-market-report

Veterinary Dermatology Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/veterinary-dermatology-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795